Test you knowledge of myelofibrosis-related anemia

Which of the following statements is correct?

For patients experiencing anemia in myelofibrosis, providers should immediately consider switching medications

For patients experiencing anemia in myelofibrosis, providers should explore alternate reasons (vitamin/mineral deficiencies)

Pacritinib is FDA approved for myelofibrosis-related anemia

Momelotinib is FDA approved for myelofibrosis-related thrombocytopenia

For patients with myelofibrosis who have anemia but otherwise no concern for progression of disease, which of the following agents might the provider consider?

Luspatercept-aamt

Erythropoiesis-stimulating agents

Transition to another JAK inhibitor (specifically one with ACVR1 inhibition)

All of the above

Which of the following best describes momelotinib’s mechanism of action?

Momelotinib inhibits JAK1/JAK2 only

Momelotinib inhibits JAK1/JAK2 and activin A receptor type 1 (ACVR1)

Momelotinib inhibits JAK2, ACVR1, and interleukin 1-associated receptor kinase (IRAK1)

Momelotinib targets JAKV167F

When should you consider using a total symptom score?

At each visit

With subjective changes in how the patient is feeling

With objective changes in laboratory values

Every 6 months

{"name":"Test you knowledge of myelofibrosis-related anemia", "url":"https://www.quiz-maker.com/Q3WGDAER9","txt":"Which of the following statements is correct?, For patients with myelofibrosis who have anemia but otherwise no concern for progression of disease, which of the following agents might the provider consider?, Which of the following best describes momelotinib’s mechanism of action?","img":"https://www.quiz-maker.com/3012/images/ogquiz.png"}

Tools: Poll Maker | Quiz Maker | Super Survey Maker